Clinical trial
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
Opening soon · Not applicable · 1 countries · Registry ID NCT07444073
Opening soonNot applicableObservational
What this study is about
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age40 Years to 89 Years
SexAll
Healthy volunteersNot accepted
ConditionAging, Obesity & Overweight
Full registry criteria
Inclusion Criteria * Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program. * BMI of ≥ 30 kg/m2 (obesity); OR * BMI of ≥ 27 kg/m2 to \< 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. Exclusion Criteria * Pregnancy or lactation. * Non-ambulatory status, total blindness, complete hearing loss, or inability to speak. * Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes. * On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months. * Active cancer on chemotherapy or immunotherapy. * Known hypersensitivity or contraindications to GLP-1 RAs. * Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.
Treatments and study arms
Not applicable. This is an observational study.
Other
Not applicable. This is an observational study.
Primary outcomes
LinAge2 Biological AgeBaseline and 6 months
The primary outcome of this study is to determine the change in LinAge2 biological age estimates in response to the NOVI Health weight management program, which comprises GLP-1 RA therapy alongside personalized diet and physical activity interventions.
Study locations
2 locations were listed when this page was built. The first 40 are shown.
NOVI Health (T3 Health PTE LTD)🇸🇬 Singapore, Singapore
Hui Ching Michelle Lee, PhDContact
Sue-Anne Ee Shiow Toh, MA MBBChir MScSub Investigator
National University of Singapore🇸🇬 Singapore, Singapore